SYK and rheumatoid arthritis: The partially selective Syk inhibitor fostamatinib showed clinical benefit in rheumatoid arthritis patients (63) and has been also investigated in other autoimmune and allergic diseases but considerable adverse events possibly due to its poor selectivity profile led to the suspension of further investigations in RA.